Oncopeptides AB (publ) (ONPPF)
USD 0.27
(0.0%)
USD 0.27
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -253.44 Million SEK | 25.83% |
| 2022 | -349.35 Million SEK | 75.41% |
| 2021 | -1.42 Billion SEK | 10.71% |
| 2020 | -1.59 Billion SEK | -115.21% |
| 2019 | -739.39 Million SEK | -76.34% |
| 2018 | -419.3 Million SEK | -69.33% |
| 2017 | -247.62 Million SEK | -116.3% |
| 2016 | -114.48 Million SEK | -114.59% |
| 2015 | -53.35 Million SEK | -61.13% |
| 2014 | -33.1 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -73.26 Million SEK | -4.53% |
| 2024 Q1 | -69.12 Million SEK | 12.67% |
| 2023 Q2 | -62.43 Million SEK | 14.17% |
| 2023 Q3 | -37.29 Million SEK | 40.26% |
| 2023 Q1 | -72.74 Million SEK | 27.66% |
| 2023 Q4 | -79.14 Million SEK | -112.2% |
| 2023 FY | -259.12 Million SEK | 25.83% |
| 2022 Q1 | -98.86 Million SEK | 74.64% |
| 2022 FY | -349.35 Million SEK | 75.41% |
| 2022 Q2 | -61.08 Million SEK | 38.21% |
| 2022 Q4 | -100.54 Million SEK | -13.16% |
| 2022 Q3 | -88.85 Million SEK | -45.45% |
| 2021 Q4 | -389.83 Million SEK | -15.03% |
| 2021 FY | -1.42 Billion SEK | 10.71% |
| 2021 Q1 | -347.33 Million SEK | 32.11% |
| 2021 Q2 | -344.83 Million SEK | 0.72% |
| 2021 Q3 | -338.91 Million SEK | 1.72% |
| 2020 Q4 | -511.57 Million SEK | -33.4% |
| 2020 Q3 | -383.49 Million SEK | 3.97% |
| 2020 Q1 | -296.87 Million SEK | -21.55% |
| 2020 FY | -1.59 Billion SEK | -115.21% |
| 2020 Q2 | -399.33 Million SEK | -34.51% |
| 2019 Q3 | -189.59 Million SEK | -10.4% |
| 2019 FY | -739.39 Million SEK | -76.34% |
| 2019 Q4 | -244.24 Million SEK | -28.82% |
| 2019 Q2 | -171.73 Million SEK | -40.85% |
| 2019 Q1 | -121.93 Million SEK | -9.64% |
| 2018 Q1 | -68.45 Million SEK | -2.62% |
| 2018 FY | -419.3 Million SEK | -69.33% |
| 2018 Q4 | -111.21 Million SEK | -7.99% |
| 2018 Q3 | -102.98 Million SEK | 28.02% |
| 2018 Q2 | -143.07 Million SEK | -109.02% |
| 2017 Q4 | -66.7 Million SEK | -29.34% |
| 2017 Q1 | -62.08 Million SEK | -21.52% |
| 2017 Q2 | -67.26 Million SEK | -8.34% |
| 2017 Q3 | -51.57 Million SEK | 23.32% |
| 2017 FY | -247.62 Million SEK | -116.3% |
| 2016 Q1 | -15.24 Million SEK | 0.0% |
| 2016 Q2 | -23.48 Million SEK | -54.05% |
| 2016 Q4 | -51.08 Million SEK | -107.11% |
| 2016 FY | -114.48 Million SEK | -114.59% |
| 2016 Q3 | -24.66 Million SEK | -5.04% |
| 2015 FY | -53.35 Million SEK | -61.13% |
| 2014 FY | -33.1 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | -3.16 Million USD | -7899.529% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -27111.987% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -9545.856% |
| Evofem Biosciences, Inc. | -17.84 Million USD | -1320.11% |
| GB Sciences, Inc. | -1.42 Million USD | -17741.985% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -7343.423% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -115062.352% |
| Skye Bioscience, Inc. | -13.67 Million USD | -1753.794% |
| Zenith Capital Corp. | -8.94 Million USD | -2734.027% |
| Agentix Corp. | -1.37 Million USD | -18376.099% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -4924.241% |
| Biomind Labs Inc. | -1 Million USD | -25003.63% |
| ContraFect Corporation | -56.88 Million USD | -345.511% |
| CSL Limited | 3.7 Billion USD | 106.846% |
| CytoDyn Inc. | -18.05 Million USD | -1303.516% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -13494.244% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -64958.141% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | -356.595% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -60901.158% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -16399.929% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -36794.534% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 409.641% |
| SQZ Biotechnologies Company | -75.82 Million USD | -234.253% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -12658.605% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | -253.059% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -8791.295% |
| Mesoblast Limited | -84.14 Million USD | -201.196% |
| Marizyme, Inc. | -34.08 Million USD | -643.54% |
| Genus plc | 6.4 Million USD | 4060.109% |
| Pharming Group N.V. | -4.87 Million USD | -5094.071% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -2935.293% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -17977.648% |
| IMV Inc. | -38.67 Million USD | -555.384% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -9113.444% |
| MultiCell Technologies, Inc. | -722.81 USD | -35064024.735% |
| ONE Bio Corp. | 13.68 Million USD | 1952.473% |
| RVL Pharmaceuticals plc | -58.99 Million USD | -329.644% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 7259.52% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -8635.786% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -3712.371% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -846077.217% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -1497.046% |
| Alpha Cognition Inc. | -9.7 Million USD | -2511.348% |
| Enzolytics Inc. | -2.14 Million USD | -11694.816% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 40.372% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -24176.533% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -8581.345% |
| Genscript Biotech Corporation | -415.79 Million USD | 39.045% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 5256.801% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -96736.768% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -10222.374% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -147674.287% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -12542.28% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 2701.468% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -5464.484% |
| Adynxx, Inc. | - USD | Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | -6665.047% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -25655.422% |
| EV Biologics, Inc. | -483.06 Thousand USD | -52366.764% |
| Q BioMed Inc. | -3.44 Million USD | -7255.637% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -20078.901% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | -361.044% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.77 Million USD | -3158.105% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -13014.234% |
| HST Global, Inc. | -140.9 Thousand USD | -179768.282% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -18878.667% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -22430.505% |
| Halberd Corporation | -75.05 Thousand USD | -337604.197% |
| Resverlogix Corp. | -12.74 Million USD | -1887.976% |
| Cell Source, Inc. | -4.32 Million USD | -5759.577% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -15947.5% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 6.69 Million USD | 3886.815% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -1454736.117% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -2.46 Million USD | -10174.49% |
| Kadimastem Ltd | -3.04 Million USD | -8236.387% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -5879.76% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -139551.762% |
| LadRx Corporation | -3.82 Million USD | -6528.446% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -36794.534% |
| Affymax, Inc. | -15.04 Million USD | -1584.481% |
| Itoco Inc. | -919.14 Thousand USD | -27474.363% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -22549.419% |
| Mobile Lads Corp. | -554.55 Thousand USD | -45603.183% |
| International Stem Cell Corporation | -663 Thousand USD | -38127.3% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| Bioxytran, Inc. | -3.82 Million USD | -6534.483% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -1006840.803% |
| Qrons Inc. | -643.67 Thousand USD | -39274.873% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -44779.879% |
| SYBLEU INC | -149.18 Thousand USD | -169793.417% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | -11265.953% |
| Rebus Holdings, Inc. | -664 Thousand USD | -38069.729% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -13853.874% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -481372.264% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -1245952.114% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | -598.856% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -15564.215% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -34343.455% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -8046.802% |
| Neutra Corp. | -229.48 Thousand USD | -110341.16% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -1345.048% |
| PureTech Health plc | -146.19 Million USD | -73.358% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | -1079.31% |
| IXICO plc | -1.43 Million USD | -17537.23% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -2570.393% |
| Gelesis Holdings, Inc. | -121.8 Million USD | -108.074% |
| CSL Limited | 3.81 Billion USD | 106.649% |
| Cellectis S.A. | -108.85 Million USD | -132.825% |